ConforMIS Inc (CFMS) Given Consensus Recommendation of “Hold” by Brokerages

ConforMIS Inc (NASDAQ:CFMS) has been assigned a consensus recommendation of “Hold” from the eight research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $4.90.

A number of brokerages have issued reports on CFMS. Canaccord Genuity cut their price target on shares of ConforMIS from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday, February 8th. Zacks Investment Research raised shares of ConforMIS from a “sell” rating to a “hold” rating in a report on Monday. Oppenheimer set a $4.00 price target on shares of ConforMIS and gave the stock a “buy” rating in a report on Thursday, February 8th. BTIG Research reissued a “hold” rating on shares of ConforMIS in a report on Thursday, November 2nd. Finally, JPMorgan Chase & Co. lowered shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd.

Shares of ConforMIS (NASDAQ:CFMS) opened at $1.49 on Tuesday. The stock has a market cap of $81.23, a price-to-earnings ratio of -1.20 and a beta of 1.41. ConforMIS has a twelve month low of $1.15 and a twelve month high of $8.61. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.19 and a quick ratio of 5.38.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. The business had revenue of $20.80 million for the quarter, compared to analyst estimates of $20.07 million. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 78.44%. The company’s revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) EPS. equities analysts expect that ConforMIS will post -0.86 earnings per share for the current year.

In other news, CFO Paul S. Weiner sold 17,723 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total transaction of $56,181.91. Following the sale, the chief financial officer now owns 162,009 shares of the company’s stock, valued at approximately $513,568.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark A. Augusti sold 16,548 shares of ConforMIS stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $37,563.96. Following the sale, the chief executive officer now directly owns 285,007 shares in the company, valued at approximately $646,965.89. The disclosure for this sale can be found here. Insiders have sold a total of 93,291 shares of company stock worth $248,077 in the last ninety days. Insiders own 9.55% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in CFMS. Granite Investment Partners LLC bought a new stake in shares of ConforMIS during the 3rd quarter valued at about $859,000. Ark Investment Management LLC boosted its stake in shares of ConforMIS by 208.5% during the 2nd quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock valued at $825,000 after purchasing an additional 130,009 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of ConforMIS by 44.0% during the 4th quarter. ARK Investment Management LLC now owns 390,564 shares of the medical instruments supplier’s stock valued at $930,000 after purchasing an additional 119,355 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of ConforMIS by 331.2% during the 3rd quarter. Citadel Advisors LLC now owns 113,972 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 87,540 shares in the last quarter. Finally, Spark Investment Management LLC boosted its stake in shares of ConforMIS by 245.3% during the 4th quarter. Spark Investment Management LLC now owns 120,500 shares of the medical instruments supplier’s stock valued at $286,000 after purchasing an additional 85,600 shares in the last quarter. 26.99% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “ConforMIS Inc (CFMS) Given Consensus Recommendation of “Hold” by Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/conformis-inc-cfms-given-consensus-recommendation-of-hold-by-brokerages.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply